GlassScriptPhysician profile
Charles P House
NPI 1225007016
$3,397.47
in general payments reported to CMS, 2019-2025
24 companies · $754 in 2025
The $754 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $353 · 2021: $407 · 2022: $427 · 2023: $339 · 2024: $602 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,605 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,605.16 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $712.04 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $517.63 | 2021-2025 | |
| Pfizer INC. | $421.82 | 2019-2025 | |
| Glaxosmithkline, LLC. | $219.90 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Allergan, INC. | $169.28 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $168.34 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.28 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.45 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $142.32 | 2021-2025 | Mounjaro, Zepbound |
| Actelion Pharmaceuticals US, INC. | $103.20 | 2023 | Opsumit, Uptravi |
| Novo Nordisk INC | $90.07 | 2019-2024 | Ozempic, Rybelsus |
| Amgen INC. | $81.68 | 2024-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $74.00 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $66.47 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.38 | 2021-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $47.78 | 2024-2025 | Inspire |
| Vanda Pharmaceuticals INC. | $43.20 | 2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $41.82 | 2022-2025 | Austedo Xr, Austedo |
| Phathom Pharmaceuticals, INC. | $34.00 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $21.08 | 2019 | |
| Corcept Therapeutics | $20.95 | 2023 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $19.66 | 2022 | |
| Mylan Specialty L.P. | $14.81 | 2024 | Yupelri |
| Merck Sharp & Dohme LLC | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles House listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.